Ramm Pharma (TSE:RAMM) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
RAMM Pharma Corp. has recently concluded a trial concerning a multimillion-dollar litigation with former CEO Sergio Martines and NATURALE SCIENCE INC, with the judge’s decision pending. The dispute involves claims and counterclaims related to contractual breaches, share purchase obligations, and fraudulent misrepresentation, with potential financial repercussions for the company’s future statements. Amidst this legal battle, RAMM continues to operate as a leader in cannabinoid pharmaceuticals, with a strong presence in Europe and a portfolio of approved products and facilities.
For further insights into TSE:RAMM stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue